Citations

Clear

421 citation(s) found for "Short, C".

Fresh Red Blood Cell Transfusion and Short-Term Pulmonary, Immunologic, and Coagulation Status: A Randomized Clinical Trial
Kor, Daryl J. , Kashyap, Rahul , Weiskopf, Richard B. , Wilson, Gregory , Buskirk, Camille M. van , Winters, Jeffrey L. , Malinchoc, Michael, Hubmayr, Rolf D., Gajic, Ognjen , Winters, Jeffrey L , Kashyap, Rahul

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | January 26, 2012 | Volume: 185 | Issue: 8 | Pages: 842-850

10.1164/rccm.201107-1332oc | PMID 22281833 Get It

Abstract Rationale Transfusion-related pulmonary complications are leading causes of morbidity and mortality attributed to transfusion. Observational studies suggest an important role for red blood cell (RBC) storage duration in these adverse outcomes. Objectives To evaluate the impact of RBC storage duration on short-term pulmonary function as well as immunologic and coagulation status in mechanically ventilated patients receiving RBC transfusion. Methods This is a double-blind, randomized, clinical trial comparing fresh (≤5 d of storage) versus standard issue single-unit RBC transfusion in adult intubated and mechanically ventilated patients. The primary outcome is the change in pulmonary gas exchange as assessed by the partial pressure of arterial oxygen to fraction of inspired oxygen concentration ratio (ΔPaO2/FiO2). Secondary outcomes include changes in immune and coagulation status. Measurements and Main Results Fifty patients were randomized to receive fresh RBCs and an additional 50 patients to standard issue RBCs. Median storage age was 4.0 days (interquartile range, 3.0–5.0) and 26.5 days (interquartile range, 21.0–36.0) in the fresh RBC group and standard issue RBC group, respectively. No differences were noted in the primary outcome of ΔPaO2/FiO2 (difference between the mean ΔPaO2/FiO2 in the standard issue RBC group vs. the fresh RBC group, –11.5; 95% confidence interval, −35.3 to 12.3; P = 0.22). Similarly, no significant differences were noted in markers of immunologic or coagulation status. Conclusions In this randomized clinical trial, no differences were noted in early measures of pulmonary function or in immunologic or coagulation status when comparing fresh versus standard issue single-unit RBC transfusion. Clinical trial registered with ClinicalTrials.gov (NCT00751322).
Small (< 10-mm) incidentally found intracranial aneurysms, Part 2: treatment recommendations, natural history, complications, and short-term outcome in 212 consecutive patients
Loumiotis, Ioannis , Brown, Robert D., Vine, Roanna , Cloft, Harry J. , Kallmes, David F. , Lanzino, Giuseppe

Mayo Clinic

Neurosurgical Focus | December 1, 2011 | Volume: 31 | Issue: 6 | Pages: E4

10.3171/2011.9.focus11237 | PMID 22133187 Get It

Object The management of incidental small unruptured intracranial aneurysms (UIAs) is controversial and many factors need to be considered in the decision-making process. The authors describe a large consecutive series of patients harboring small incidental intracranial aneurysms. Treatment strategy, natural history, complications, and short-term outcomes are presented. Methods Between January 2008 and May 2011, the authors prospectively evaluated 212 patients with 272 small (< 10-mm) incidental aneurysms. Treatment recommendations (observation, endovascular treatment, or surgery), complications of treatment, and short-term outcomes were assessed. Results Recommended treatment consisted of observation in 125 patients, endovascular embolization in 64, and surgery in 18. Six patients were excluded from further analysis because they underwent treatment elsewhere. In the observation group, at a mean follow-up of 16.7 months, only 1 patient was moved to the embolization group. Seven (6%) of the 125 patients in the observation group died of causes unrelated to aneurysm. Sixty-five patients underwent 69 embolization procedures. The periprocedural permanent morbidity and mortality rates in patients undergoing endovascular treatment were 1.5% and 1.5%, respectively (overall morbidity and mortality rate 3.0%). In the surgery group no periprocedural complications were observed, although 1 patient did not return to her previous occupation. No aneurysmal rupture was documented in any of the 3 treatment groups during the follow-up period. Conclusions A cautious and individualized approach to incidental UIAs is of utmost importance for formulation of a safe and effective treatment algorithm. Invasive treatment (either endovascular or surgery) can be considered in selected younger patients, certain “higher-risk” locations, expanding aneurysms, patients with a family history of aneurysmal hemorrhage, and in those who cannot live their lives knowing that they harbor the UIA. Although the complication rate of invasive treatment is very low, it is not negligible. The study confirms that small incidental UIAs deemed to be not in need of treatment have a very benign short-term natural history, which makes observation a reasonable approach in selected patients.
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease
Lacy, Martha Q. , Allred, Jacob B., Hayman, Suzanne R. , Short, Kristen Detweiler, Dispenzieri, Angela , Kumar, Shaji , Greipp, Philip R., Lust, John A., Russell, Stephen J. , Dingli, David , Zeldenrust, Steven R., Fonseca, Rafaël , Bergsagel, P. Leif , Stewart, A. Keith, Laumann, Kristina, Mandrekar, Sumithra J. , Reeder, Craig B. , Rajkumar, S. Vincent , Gertz, Morie A. , Buadi, Francis K. , Roy, Vivek , Mıkhael, Joseph , Bergsagel, P. Leif , Rajkumar, S Vincent , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Fonseca, Rafael

Mayo Clinic

Blood | June 20, 2011 | Volume: 118 | Issue: 11 | Pages: 2970-2975

10.1182/blood-2011-04-348896 | PMID 21690557 Get It

Abstract Pomalidomide at doses of 2 or 4 mg/d has demonstrated excellent activity in patients with multiple myeloma (MM). We opened 2 sequential phase 2 trials using the pomalidomide with weekly dexamethasone (Pom/dex) regimen at differing doses to study the efficacy of this regimen in patients who have failed both lenalidomide and bortezomib. Pomalidomide was given orally 2 or 4 mg daily with dexamethasone 40 mg weekly. Thirty-five patients were enrolled in each cohort. Confirmed responses in the 2-mg cohort consisted of very good partial response (VGPR) in 5 (14%), partial response (PR) in 4 (11%), minor response (MR) in 8 (23%) for an overall response rate of 49%. In the 4-mg cohort, confirmed responses consisted of complete response (CR) in 1 (3%), VGPR in 3 (9%), PR in 6 (17%), MR in 5 (14%) for an overall response rate of 43%. Overall survival at 6 months is 78% and 67% in the 2- and 4-mg cohort, respectively. Myelosuppression was the most common toxicity. This nonrandomized data suggests no advantage for 4 mg over the 2 mg daily. Pomalidomide overcomes resistance in myeloma refractory to both lenalidomide and bortezomib. This trial is registered at http://ClinicalTrials.gov, number NCT00558896.
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma
Madan, Sumit , Lacy, Martha Q. , Dispenzieri, Angela , Hayman, Suzanne R. , Detweiler‐Short, Kristen, Dingli, David , Zeldenrust, Steven R., Lust, John A., Greipp, Philip R., Rajkumar, S. Vincent , Kumar, Shaji , Gertz, Morie A. , Buadi, Francis K. , Rajkumar, S Vincent , Dispenzieri, Angela , Dingli, David

Mayo Clinic

Blood | June 15, 2011 | Volume: 118 | Issue: 7 | Pages: 1763-1765

10.1182/blood-2011-04-350009 | PMID 21673347 Get It

AbstractThe efficacy of retreatment with immunomodulatory drugs (IMiDs) among patients with multiple myeloma who received this class of drugs for initial therapy is unknown. We studied 140 patients who received either thalidomide-dexamethasone (81; 58%) or lenalidomide-dexamethasone (59; 42%) as first-line therapy of multiple myeloma followed by repeat IMiD (thalidomide [34; 24%] or lenalidomide [106; 76%]) as one of the salvage regimens. A median of 2 treatments (range, 1-6), including a stem cell transplant in 105 patients (75%), were administered before IMiD-based salvage therapy. The median time from diagnosis to repeat exposure to IMiD was 28 months. Among the 113 evaluable patients, 50 (44%) achieved at least a partial response, and 63 (56%) achieved less than a partial response to repeat IMiD. Response rates with lenalidomide retreatment were higher than with repeat administration of thalidomide.
Preliminary Analysis of the Feasibility and Safety of Salvage Robot-Assisted Radical Prostatectomy After Radiation Failure: Multi-Institutional Perioperative and Short-Term Functional Outcomes
Chauhan, Sanket, Patel, Manoj , Coelho, Rafael F. , Liss, Michael A. , Rocco, Bernardo , Sivaraman, Ananth K., Palmer, Kenneth J. , Coughlin, Geoffrey D. , Ferrigni, Robert G., Castle, Erik P., Ahlering, Thomas E. , Parra-Davila, Eduard, Patel, Vipul , Sivaraman, Ananthakrishnan , Parra‐Dávila, Eduardo

Mayo Clinic

Journal of Endourology | May 13, 2011 | Volume: 25 | Issue: 6 | Pages: 1013-1019

10.1089/end.2010.0564 | PMID 21568696 Get It

Ulcerative Colitis–Associated Colorectal Cancer Arises in a Field of Short Telomeres, Senescence, and Inflammation
Risques, Rosa Ana , Lai, Lisa A. , Himmetoğlu, Çiğdem, Ebaee, Anoosheh, Feng, Ziding , Bronner, Mary P. , Al-Lahham, Bassel, Lindor, Keith D. , Rabinovitch, Peter S. , Brentnall, Teresa A. , Li, Lin , Kowdley, Kris V.

Mayo Clinic

Cancer Research | March 3, 2011 | Volume: 71 | Issue: 5 | Pages: 1669-1679

10.1158/0008-5472.can-10-1966 | PMID 21363920 Get It

Abstract Inflammation plays a role in the progression to cancer and it is linked to the presence of senescent cells. Ulcerative colitis (UC) is a chronic inflammatory disease that predisposes to colorectal cancer. Tumorigenesis in this setting is associated with telomere shortening that can be observed in the nondysplastic epithelium of UC patients with high-grade dysplasia (HGD) or cancer (UC progressors). We hypothesized that a preneoplastic field of inflammation, telomere shortening, and senescence underlies tumor progression in UC progressors. Multiple biopsies of varying histologic grade were collected along the colon of nine UC progressors and analyzed for telomere length, DNA damage, senescence, p53, p16, and chronic and acute inflammation. Twenty biopsies from four UC nonprogressors and twenty-one biopsies from control individuals without UC were also analyzed. Short telomeres and increased DNA damage, senescence, and infiltrating leukocytes were observed in biopsies located less than 10 cm from HGD or cancer. Low-grade dysplasia (LGD) had the shortest telomeres along with the highest levels of senescence and infiltrating leukocytes, whereas HGD biopsies showed the opposite pattern. The expression of p16 and p53 was low in nondysplastic biopsies but progressively increased in LGD and HGD. In addition, high levels of infiltrating leukocytes were associated with telomere shortening, senescence, and reduced p53 expression. These results suggest that dysplasia arises in a preneoplastic field of chronic inflammation, which leads to telomere shortening, DNA damage, and senescence. Our findings argue that senescence acts as a tumor suppressor mechanism that is abrogated during the transition from LGD to HGD in UC. Cancer Res; 71(5); 1669–79. ©2011 AACR.
Randomized, Double-Blinded, Placebo-Controlled Crossover Trial of Treating Erectile Dysfunction with Sildenafil After Radiotherapy and Short-Term Androgen Deprivation Therapy: Results of RTOG 0215
Bruner, Deborah Watkins , James, J., Bryan, Charlene, Pisansky, Thomas M. , Rotman, Marvin, Corbett, Thomas, Speight, Joycelyn L., Byhardt, Roger W., Bentzen, Søren M. , Kachnic, Lisa A. , Berk, Lawrence , Sandler, Howard M. , Bruner, Deborah , Bentzen, Soren M

Mayo Clinic

The Journal of Sexual Medicine | January 14, 2011 | Volume: 8 | Issue: 4 | Pages: 1228-1238

10.1111/j.1743-6109.2010.02164.x | PMID 21235716 Get It

ABSTRACT Introduction Erectile dysfunction (ED) may be the most commonly observed adverse event (AE) associated with the combination of radiation therapy (RT) and androgen deprivation therapy (ADT). A significant number of men are trying phosphodiesterase type 5 inhibitors (PDE5s) such as sildenafil to treat ED, yet sildenafil studies to date shed little light on the response to ED after ADT. Aim The purpose of this trial was to evaluate sildenafil in the treatment of ED in prostate cancer patients previously treated with external beam RT and neoadjuvant and concurrent ADT. Methods In this randomized, double-blinded crossover trial, eligible patients received RT/ADT for intermediate risk prostate cancer and currently had ED as defined by the International Index of Erectile Function (IIEF). Patients were randomized to 12 weeks of sildenafil or placebo followed by 1 week of no treatment then 12 weeks of the alternative. Treatment differences were evaluated using a marginal model for binary crossover data. Main Outcome Measures The primary end point was improved erectile function, as measured by the IIEF. Results The study accrued 115 patients and 61 (55%) completed all three IIEF assessments. Sildenafil effect was significant (P = 0.009) with a difference in probabilities of erectile response of 0.17 (95% confidence interval: 0.06, 0.29), and 0.21 (0.06, 0.38) for patients receiving ≤120 days of ADT. However, as few as 21% of patients had a treatment-specific response, only improving during sildenafil but not during the placebo phase. Conclusions This is the first controlled trial to suggest a positive sildenafil response for ED treatment in patients previously treated with RT/ADT, however, only a minority of patients responded to treatment. ADT duration may be associated with response and requires further study. The overall low response rate suggests the need for study of additional or preventative strategies for ED after RT/ADT for prostate cancer.
Short-term outcomes after elective minimally invasive colectomy for diverticulitis
Pendlimari, Rajesh, Touzios, John G., Azodo, Ijeoma A. , Dozois, Eric J. , Larson, Dirk, Chua, Hui Kheng , Cima, Robert R.

Mayo Clinic

Journal of British Surgery | November 25, 2010 | Volume: 98 | Issue: 3 | Pages: 431-435

10.1002/bjs.7345 | PMID 21254022 Get It

Abstract Background The role of minimally invasive surgery in complicated diverticulitis is still being elucidated. The aim of this study was to compare short-term outcomes in patients undergoing minimally invasive surgery for complicated or uncomplicated diverticular disease. Methods All patients who had elective minimally invasive surgery for diverticulitis between 2003 and 2008 were identified from a prospectively maintained database. Complicated disease was defined as diverticulitis associated with abscess, fistula, stricture or bleeding. Univariable analysis was performed to compare safety and short-term outcomes in patients with complicated and uncomplicated diverticulitis. Results A total of 361 patients (136 with complicated and 225 with uncomplicated diverticulitis) were operated on with either a laparoscopic (36·0 per cent) or a hand-assisted laparoscopic (64·0 per cent) surgical technique. There were no significant differences between the groups with respect to age, sex, body mass index, laparoscopic approach, postoperative recovery protocol or previous open surgery. Conversion rates were similar for complicated and uncomplicated disease (14·0 versus 11·6 per cent respectively; P = 0·514). There was no difference between the groups with respect to return of bowel function (mean 3·1 versus 3·2 days respectively; P = 0·156), morbidity (27·9 versus 19·6 per cent; P = 0·070) or mean length of stay (5·4 versus 4·8 days; P = 0·186). There were no deaths within 30 days. Conclusion Elective minimally invasive colectomy is feasible for patients with uncomplicated and complicated diverticulitis, with equivalent outcomes.
Short-Term Cardiac and Noncardiac Mortality Following Liver Transplantation
Eleid, Mackram F. , Hurst, R. Todd, Vargas, Hugo E. , Rakela, Jorge , Appleton, Christopher P., Mulligan, David C. , Vargas, Hugo E

Mayo Clinic

Journal of Transplantation | August 12, 2010 | Volume: 2010 | Issue: No issue available | Pages: 1-7

10.1155/2010/910165 | PMID 20814597 Get It

Objectives. To determine the importance of acute cardiac events as a cause of mortality compared to non-cardiac events in the four month period following liver transplantation (LT) using current preoperative cardiac screening strategies.Patients and Methods. We retrospectively reviewed timing, type, and outcome of adverse cardiac events, and all cause mortality in the 4 month postoperative period in 393 consecutive LT patients from October 1999 to February 2008.Results. Of 30 total deaths (7.6% overall mortality rate), 27 (90%) were due to surgical or medical complications and 3 (10%) were primary cardiac deaths (0.8% cardiac mortality rate). Acute cardiac events occurred in 26 patients (6.6%), including 13 arrhythmias (50%), 7 new onset heart failures (27%), and 6 myocardial infarctions (23%). Twelve of 13 intraoperative events were arrhythmias (92%) including two of three cardiac deaths.Conclusions. Using current preoperative screening recommendations, deaths from primary cardiac events within four months of LT are very uncommon (0.8%), especially compared with deaths related to medical and surgical complications (6.9%).
Short-term repeatability of joint space width measurements using a magnetic resonance imaging compatible knee positioning device
Stanley, Douglas, Weishaar, Paul , Amrami, Kimberly K. , Kaufman, Kenton R. , Koff, Matthew F. , Kaufman, Kenton R

Mayo Clinic

Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine | February 15, 2010 | Volume: 224 | Issue: 9 | Pages: 1061-1071

10.1243/09544119jeim735 | PMID 21053771 Get It

The purpose of this study was to evaluate a magnetic resonance imaging (MRI) compatible knee positioning device to aid in minimizing intratechnologist and intertechnologist differences of minimum joint space width (JSW) measurements. Five subjects were scanned by two separate technologists, with and without an MRI-compatible positioning device. A semi-automated program calculated the minimum JSW of the tibiofemoral and patellofemoral joints. The scan-to-scan repeatability was evaluated from measurements between serial scans without subject repositioning, and the intratechnologist and intertechnologist repeatabilities were evaluated when the subject was removed from the magnet and repositioned by an individual technologist. The root mean square (RMS) error of the JSW measurements was also calculated. All measures of scan-to-scan repeatability and intratechnologist repeatability were unchanged with the MRI-compatible positioning device. The intertechnologist repeatability decreased from 0.70 to 0.42 mm, and the RMS error was significantly reduced ( P = 0.0006) from 0.26 to 0.15 mm for the tibiofemoral joint. The variability of patellofemoral JSW measurements increased when using the positioning device; however, the increases were not statistically significant. The intertechnologist repeatability increased from 1.55 to 1.79 mm, and the RMS error increased from 0.58 to 0.73 mm. The MRI-compatible positioning device was successful at reducing JSW measurement variability at the tibiofemoral joint. The increase in measurement variability at the patellofemoral joint may be due to local incongruities of the articular surfaces. An MRI-compatible positioning device may be beneficial for quantitative longitudinal studies evaluating knee joint health.